Publication

Video

Supplements and Featured Publications

Novel Emerging Therapies in Relapsed/Refractory AML
Volume1
Issue 1

Dr. Becker on the Rationale for Investigating Uproleselan in Combination with Chemotherapy in AML

Pamela S. Becker, MD, PhD, discusses the rationale for investigating uproleselan in combination with chemotherapy in relapsed/refractory acute myeloid leukemia.

Pamela S. Becker, MD, PhD, Department of Hematologic Malignancies, City of Hope, discusses the rationale for investigating uproleselan (GMI-1271) in combination with chemotherapy in relapsed/refractory acute myeloid leukemia (AML).

Preclinical studies of uproleselan done in Australia by a group led by investigator Ingrid Winkler showed that AML cells in mice enhanced proinflammatory mediators, which increased E-selectin expression in the bone marrow microenvironment, Becker says. Additionally, this research demonstrated mediators expressed by AML could not up-regulate the E-selectin, due to prevention from the TNFα blockade , Becker explains.

Moreover, preclinical work with uproleselan generated a decrease to the pro-survival pathways that are active in the AML, Becker continues. This process sensitized the AML cells to chemotherapy, Becker continues. Mouse models elicited an improved survival of mice if they were treated with chemotherapy plus the uproleselan, vs chemotherapy alone, Becker concludes.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Addressing Unmet Needs in HER2+ Metastatic BTC
Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Apr 18th 2025 - Apr 19th 2026

online-activity
Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina
Video

Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina

Apr 17th 2025 - May 23rd 2025

online-activity
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota
Video

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota

Apr 17th 2025 - May 23rd 2025

online-activity